When to Do Tumor Genomic Profiling in Advanced Prostate Cancer and What?

September 08, 2024

Videos

PEER-TO-PEER CLINICAL CONVERSATIONS

Epidemiology Applied to Focal Therapy in Prostate Cancer: Where Do We Stand?

Kae Jack Tay, MBBS, MRCS, MMed, MCI, FAMS
Zach Klaassen interviews Jack Tay about the evolution and current practices in focal therapy for prostate cancer. Dr. Tay discusses the precision and reduced toxicity offered by focal therapy, which targets only cancerous tissues within the prostate, sparing non-cancerous areas.

VIEW VIDEO

Integrating Genetic Variants and Clinical Factors for Improved Prostate Cancer Prognostication

Susan Halabi, PhD
Susan Halabi discusses her presentation on prognostic factors in metastatic castration-resistant prostate cancer based on the Alliance trial. The phase three trial, which enrolled 1,311 patients, compared the effects of enzalutamide alone to enzalutamide combined with abiraterone and prednisone.

VIEW VIDEO

Extracellular Vesicles in Prostate Cancer: Multi-Omic Liquid Biopsy

Irene Casanova-Salas, MD, PhD, and Joaquin Mateo, MD, PhD
Andrea Miyahira discusses with Irene Casanova-Salas and Joaquin Mateo a Cancer Cell publication on using circulating tumor extracellular vesicles (EVs) to monitor metastatic prostate cancer evolution. The researchers describe their novel method for analyzing both DNA and RNA from EVs in patient plasma samples.

VIEW VIDEO

Articles

SELECTED TOPICAL CONTENT

Development and Validation of a Multi-Institutional Nomogram of Outcomes for PSMA-PET–Based Salvage Radiotherapy in Recurrent Prostate Cancer

Constantinos Zamboglou, MD

Constantinos Zamboglou presents the development and validation of a multi-institutional nomogram for patients undergoing PSMA-PET-guided salvage radiotherapy (sRT) for biochemically recurrent prostate cancer following radical prostatectomy. The study analyzed 1,029 patients from 11 institutions, using factors such as pre-SRT PSA, ISUP grade, and nodal recurrence to predict outcomes, with a validated nomogram showing a concordance index of 0.7 for freedom from biochemical failure.

Artificial Intelligence: Innovation and Potential for Diagnostic Imaging in Prostate Cancer

Stephanie Harmon, PhD

Stephanie Harmon discusses the potential of artificial intelligence (AI) in prostate cancer diagnostic imaging. AI applications span areas such as quality control, organ and lesion segmentation, and treatment planning. Dr. Harmon highlighted challenges in multiparametric MRI, including variability in image quality and interpretation, while emphasizing the importance of public AI datasets and validation. AI’s role in advanced imaging, particularly PSMA PET/CT, shows promise but faces challenges such as inter-reader variability and technical needs.

Clinical Utility of Transcriptomic Signatures to Identify Androgen Receptor and Neuroendocrine Signaling in Prostate Cancer

Yu-Wei Chen, MD, MS

Yu-Wei Chen presents on the clinical utility of transcriptomic signatures in identifying androgen receptor (AR) and neuroendocrine (NE) signaling in prostate cancer. This study analyzed 4,476 prostate tumors, revealing distinct molecular subtypes based on AR and NE signatures, with NE+ tumors showing more aggressive features and poorer overall survival. These findings emphasize the importance of understanding molecular subtypes to inform personalized treatment strategies, especially in advanced prostate cancer, and will be used in the PREDICT trial to guide treatment regimens for metastatic castration-resistant prostate cancer.